{
    "clinical_study": {
        "@rank": "40162", 
        "arm_group": [
            {
                "arm_group_label": "AMP-110", 
                "arm_group_type": "Experimental", 
                "description": "Escalating doses of AMP-110"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1, single-dose, placebo-controlled, dose-escalation,multi-center, first time\n      in human study of AMP-110 in adult subjects with rheumatoid arthritis."
        }, 
        "brief_title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be able to provide written informed consent\n\n          -  Body mass index 18.5 to 35.0 kg/m2\n\n          -  Diagnosis of Rheumatoid Arthritis according to 1987 revised American College of\n             Rheumatology (ACR) criteria\n\n          -  Global Functional Class I, II, or III according to ACR 1991 revised criteria\n\n          -  Stable use of >/= 1 Disease Modifying Anti-rheumatic Drugs (DMARD) for >/= 4 weeks\n             prior to Day 0, including:\n\n               1. Methotrexate (MTX) 7.5 - 25 mg/week\n\n               2. Hydroxychloroquine (HCQ) </= 400 mg/day\n\n               3. Sulfasalazine (SSZ) 1,000 - 3,000 mg/day\n\n               4. Leflunomide 5 - 20 mg/day\n\n               5. Azathioprine 150 mg/day or 2 mg/kg/day\n\n               6. Combinations of MTX, HCQ, and/or SSZ allowed\n\n        Exclusion Criteria:\n\n          -  Prior to Day 0, use of\n\n               1. Abatacept\n\n               2. Rituximab within 6 months\n\n               3. Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or\n                  Mycophenolate mofetil within 2 months\n\n               4. Etanercept or Anakinra within 28 days\n\n               5. Immunoglobulin or blood products within 28 days\n\n          -  Evidence of any active or recent infection including ongoing, chronic infectious\n             disease such as chronic renal infection or chronic chest infection with\n             bronchiectasis or sinusitis\n\n          -  History of systemic autoimmune disease other than Rheumatoid Arthritis\n\n          -  History of allergic reactions to other protein therapeutics such as monoclonal\n             antibodies or fusion proteins\n\n          -  History of anaphylaxis or allergic diathesis\n\n          -  Clinically significant cardiac disease, including: unstable angina; myocardial\n             infarction within 6 months; congestive heart failure; arrhythmia requiring active\n             therapy, with the exception of clinically insignificant extrasystoles, or minor\n             conduction abnormalities; and history of clinically significant abnormality on\n             electrocardiogram\n\n          -  Evidence of active or latent tuberculosis\n\n          -  Vaccination wtih live attenuated viruses within the 2 weeks prior to Day 0\n\n          -  Evidence of infection with hepatitis B virus, hepatitis C virus, human\n             immunodeficiency virus 1 or 2, or active infection with hepatitis A\n\n          -  Pregnant or breastfeeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878123", 
            "org_study_id": "AMP-110-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "AMP-110", 
                "description": "Dose levels 1 through 6: Single intravenous infusion on Day 0", 
                "intervention_name": "AMP-110", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Dose levels 4 through 6: Single intravenous infusion on Day 0", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antirheumatic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Arthritis", 
            "Rheumatoid Arthritis", 
            "Joint Diseases", 
            "Musculoskeletal Diseases", 
            "Rheumatic Diseases", 
            "Connective Tissue Diseases", 
            "Autoimmune Diseases", 
            "Immune System Diseases", 
            "Antirheumatic agents"
        ], 
        "lastchanged_date": "December 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36207"
                    }, 
                    "name": "Pinnacle Research Group, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34239"
                    }, 
                    "name": "Sarasota Arthritis Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Altoona Center for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Metroplex Clinical Research Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis", 
        "other_outcome": [
            {
                "description": "Determine if pharmacodynamics effects of AMP-110 on certain cytokine levels and T cell subsets are dependent on serum drug concentrations", 
                "measure": "Assess pharmacokinetic and pharmacodynamic relationships", 
                "safety_issue": "No", 
                "time_frame": "From Day 0 pre-dose through Day 56"
            }, 
            {
                "description": "Blood samples will be analyzed throughout the study to characterize the physiological effects of AMP-110 treatment and to determine markers that correlate with response to treatment", 
                "measure": "Evaluate exploratory biomarkers", 
                "safety_issue": "No", 
                "time_frame": "From start of study drug administration through Day 56"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluate number of subjects with dose-limiting toxicities (through Day 14), evaluate number of subjects wtih adverse events (through Day 56), and number of subjects wtih changes from baseline in laboratory values, vital signs, physical exam and electrocardiogram (through Day 56)", 
                "measure": "Evaluate the safety and tolerability of a single dose of AMP-110 versus placebo", 
                "safety_issue": "Yes", 
                "time_frame": "From start of study drug administration through Day 56"
            }, 
            {
                "description": "Based on the occurrence of dose-limiting toxicities (through Day 14)", 
                "measure": "Determine Maximum Tolerated Dose and/or recommended dose level(s) for future clinical trials", 
                "safety_issue": "Yes", 
                "time_frame": "From start of study drug administration through Day 56"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878123"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacokinetics evaluated by area under the serum concentration versus time curve (AUC), peak serum concentration (Cmax), and clearance (Cl) of AMP-110", 
            "measure": "Evaluate pharmacokinetic profile of a single dose of AMP-110", 
            "safety_issue": "No", 
            "time_frame": "From Day 0 pre-dose through Day 28"
        }, 
        "source": "Amplimmune", 
        "sponsors": {
            "collaborator": {
                "agency": "Daiichi Sankyo Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Amplimmune", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}